Mechanisms of Resistance and Treatment of Relapse after CAR T-cell Therapy for Large B-cell Lymphoma and Multiple Myeloma
Author:
Publisher
Elsevier BV
Subject
Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy
Reference177 articles.
1. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study;Berdeja;Lancet,2021
2. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma;Locke;N Engl J Med,2022
3. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study;Shah;Lancet,2021
4. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial;Jacobson;Lancet Oncol,2022
5. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma;Wang;N Engl J Med,2020
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Several factors that predict the outcome of large B‐cell lymphoma patients who relapse/progress after chimeric antigen receptor (CAR) T‐cell therapy can be identified before cell administration;Cancer Medicine;2024-09
2. CAR-T cell therapy in relapsed or refractory multiple myeloma and access in Turkey;Frontiers in Medicine;2024-08-28
3. Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features;Cellular Oncology;2024-08-27
4. Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed/refractory multiple myeloma;Frontiers in Oncology;2024-08-08
5. ASTCT Committee on Practice Guidelines Survey on Evaluation and Management of Relapsed/Refractory Multiple Myeloma after Failure of Chimeric Antigen Receptor T Cell Therapy;Transplantation and Cellular Therapy;2024-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3